Finally, a nightly clonidine
with once-a-day extended-release

With a single nighttime dose, ONYDA™ XR (clonidine HCI) enables a smooth continuous release throughout the day1

Mean clonidine concentration-time profiles after single dose administration of ONYDA XR vs twice-a-day clonidine hydrochloride extended-release tablets (clonidine XR)1

onyda xr adhd pk data chart

Study details: Following a single 0.2 mg dose of ONYDA XR in 20 healthy adult subjects under fasting conditions in a crossover study, the median (range) time to peak plasma concentrations (Tmax) for clonidine XR was 7.50 (4 –17) hours after dosing. Peak concentration (Cmax) was 95.6% of the Cmax of clonidine XR 0.1 mg administered at 0 and 12 hours under fasting conditions.1

The relative bioavailability of ONYDA XR compared with an equal dose of clonidine XR was 96.1%.1

Food had no effect on plasma exposures of clonidine after administration of ONYDA XR.1

REFERENCES: 1. ONYDA XR [package insert]. Tris Pharma, Inc., Monmouth Junction, NJ.

Back to Top arrow up
IMPORTANT SAFETY INFORMATION

ONYDA™ XR (clonidine HCI) is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older.

See Additional Important Safety Information.

INDICATION

ONYDA™ XR (clonidine HCI) is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older.

IMPORTANT SAFETY INFORMATION

Contraindications:

ONYDA XR is contraindicated in patients with history of a hypersensitivity reaction to clonidine.

Warnings & Precautions:

Adverse Reactions:

Clinically Important Drug Interactions:

Use in Specific Populations:

To report SUSPECTED ADVERSE REACTIONS, contact Tris Pharma, Inc. at 1-732-940-0358 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see ONYDA XR PI for Full Prescribing Information.

You are now leaving this website

You are about to leave ONYDAhcp.com and enter a website operated by a third party. Would you like to continue?

Yes
×
Interested in more information?

To learn more about Tris ADHD products, or to speak to a representative, please click below.

Request Info
up arrowTop